Clinical Trials Directory

Trials / Unknown

UnknownNCT05622123

BetaFIT Study: Beta Cell Imaging After Faecal mIcrobiota Transplantation

The Effects of Faecal Microbiota Transplantation on Beta Cell Preservation in Patients With Newly Diagnosed Type 1 Diabetes

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
Radboud University Medical Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The main goal is to investigate whether beta cell mass is correlated to beta cell function after autologous faecal microbial transplantation (FMT) in patients with newly diagnosed type 1 diabetes

Detailed description

The incidence of Type 1 Diabetes Mellitus (T1D) has tripled in the last thirty years, and T1D is associated with a lifelong increase of considerable morbidity and mortality compared to healthy subjects. As the increased T1D incidence is primarily observed in subjects who are not genetically predisposed, environmental factors including altered diet, antibiotic use as well as mode of birth have been suggested to play a role, and these factors have invariably been linked to changes in the gut microbiome. Indeed, an altered composition of the faecal microbiota composition was observed in adolescent T1D patients. A previous study by de Groot et al. (2021) showed that faecal microbiota transplantation stops the decline in endogenous insulin production in newly diagnosed type 1 diabetes patients. However, it is unknown whether this is due to an increase in beta cell mass, or increased function of the remaining beta cells. In this study, the investigators aim to investigate whether beta cell mass (quantified by 68Ga-NODAGA-exendin-4 PET/CT imaging) is correlated to beta cell function after autologous faecal microbial transplantation in patients with newly diagnosed type 1 diabetes.

Conditions

Interventions

TypeNameDescription
DRUG68Ga-NODAGA-Exendin-4PET/CT imaging after injection with 68Ga-NODAGA-exendin-4

Timeline

Start date
2023-02-23
Primary completion
2024-02-28
Completion
2024-03-30
First posted
2022-11-18
Last updated
2023-04-04

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT05622123. Inclusion in this directory is not an endorsement.